Chi-Med Initiates Rolling Submission of NDA to U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Daniel Sontupe
Market Access

Brenda Snow
Authentic Patient Voice

David Linetsky
Point-of-Care Marketing

Joey Cohen
Medication Adherence

Amy Giles
Increasing Engagement

Bud Bilanich
Success Coach

Matt Turner
Patient Affordability

Pat Purcell
Meeting Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Stacey Gandler
Brand Nourishment